The following is a summary of “Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque ...

Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

Deucravacitinib significantly improved skin-related quality of life of patients with moderate to severe plaque psoriasis, ...

Jack Danilkowicz appointed as Chief Commercial Officer; bringing extensive experience successfully planning and executing commercial strategies ...

Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching and maintained long-term ...

Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been ...

AX-158 has achieved clinical validation through its phase 2a trial for the treatment of patients with mild to moderate plaque ...

The "Plaque Psoriasis Market by Treatment, by Route of Administration, by End-user, and by Region" report has been added to ...

Novel breakthrough: first molecule to modulate the fundamental mechanism of T cell activation underlying autoimmune pathology ...

Emkay Global Financial is bullish on Sun Pharma has recommended buy rating on the stock with a target price of Rs 2400 in its ...

psoriasis drugs market is expected to expand significantly, growing from an estimated USD 19.65 billion in 2024 ...

Turmeric's active compound, curcumin, is a potent anti-inflammatory and antioxidant that can help with conditions like ...